Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 4.940
-0.060 (-1.20%)
At close: Jun 25, 2026
EGX:RMDA Revenue
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had revenue of 1.07B EGP in the quarter ending March 31, 2026, with 23.24% growth. This brings the company's revenue in the last twelve months to 4.30B, up 35.21% year-over-year. In the year 2025, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had annual revenue of 4.10B with 47.94% growth.
Revenue (ttm)
4.30B
Revenue Growth
+35.21%
P/S Ratio
2.30
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.10B | 1.33B | 47.94% |
| Dec 31, 2024 | 2.77B | 846.34M | 44.03% |
| Dec 31, 2023 | 1.92B | 438.40M | 29.54% |
| Dec 31, 2022 | 1.48B | 237.52M | 19.06% |
| Dec 31, 2021 | 1.25B | 286.27M | 29.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition